The independent PlasmaMATCH trial, in which patients with MBC were enrolled based on detection of an activating HER2 mutation in circulating tumor DNA (ctDNA), reported that neratinib as monotherapy or combined with fulvestrant showed comparable clinical activity when patients were selected using this technique versus when the selection was guided by tissue testing, supporting the utility of ctDNA analysis in this patient population[21]. This evidence concerns the gene ERBB2 and neoplasm.